Access Pharmaceuticals MuGard on Formulary at Memorial Sloan-Kettering Cancer Center
Published: Apr 03, 2012
DALLAS and NEW YORK, April 4, 2012 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that Memorial Sloan-Kettering Cancer Center (MSKCC) has added MuGard to its cancer supportive care pharmacy formulary. Patients undergoing cancer treatment will now have direct access to MuGard from the first day of cancer treatment to manage oral mucositis, characterized by inflammation and erythema or ulcerations throughout the oral mucosa.
"Having a world-renowned institution like Memorial Sloan-Kettering add MuGard to its formulary is a monumental step in our mission to increase MuGard access for cancer patients," said Frank Jacobucci, Vice President Sales and Marketing, Access Pharmaceuticals, Inc. He continued, "Dedicated to the progressive control and cure of cancer, MSKCC is considered one of the best cancer treatment institutions in the world and we are pleased that it has taken action, after their evaluation of MuGard, to treat and potentially eliminate oral mucositis, a debilitating side effect that is often times detrimental to anticancer treatments and lessens the quality of life for cancer patients.
As one of the world's premier cancer centers, Memorial Sloan-Kettering Cancer Center is committed to exceptional patient care, leading-edge research, and superb educational programs. Recognized around the world for excellence, Memorial Sloan-Kettering Cancer Center is consistently ranked as one of the nation's top two cancer centers by U.S. News & World Report. It is designated by the National Cancer Institute as a Comprehensive Cancer Center and is a member of the National Comprehensive Cancer Network.
Conference Call details:
The investor conference will be held today at 11:00 am ET. Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.
A replay of the call will be available starting on April 4, 2012 at 1:00 pm ET, through April 18, 2012 until 11:59 pm ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 377785.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.
The company also has other advanced drug delivery technologies including CobaCyte-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
Company and Media Contact:
Contact: Investor Relations
Donald C. Weinberger
Director of Investor Relations
Wolfe Axelrod Weinberger Assoc. LLC
Access Pharmaceuticals, Inc.
SOURCE Access Pharmaceuticals, Inc.